[go: up one dir, main page]

MX2013012429A - Una composicion de entacopone. - Google Patents

Una composicion de entacopone.

Info

Publication number
MX2013012429A
MX2013012429A MX2013012429A MX2013012429A MX2013012429A MX 2013012429 A MX2013012429 A MX 2013012429A MX 2013012429 A MX2013012429 A MX 2013012429A MX 2013012429 A MX2013012429 A MX 2013012429A MX 2013012429 A MX2013012429 A MX 2013012429A
Authority
MX
Mexico
Prior art keywords
composition
entacapone
entacopone
pvpk30
sds
Prior art date
Application number
MX2013012429A
Other languages
English (en)
Inventor
Wei-Hua Hao
Jong-Jing Wang
hui-yun Chen
Original Assignee
Innopharmax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innopharmax Inc filed Critical Innopharmax Inc
Publication of MX2013012429A publication Critical patent/MX2013012429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describe una composición de entacapone que comprende entacapone o sales farmacéuticamente aceptables, PVPK30 y SDS en la presente invención, en donde la proporción en masa de entacapone: PVPK30: SDS es de 1:0.05~0.6:0.06~0.1. La presente invención describe también métodos de preparación y uso de la composición de entacapone.
MX2013012429A 2011-04-26 2011-04-26 Una composicion de entacopone. MX2013012429A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/073297 WO2012145893A1 (zh) 2011-04-26 2011-04-26 安它可朋组合物

Publications (1)

Publication Number Publication Date
MX2013012429A true MX2013012429A (es) 2013-12-06

Family

ID=47071548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012429A MX2013012429A (es) 2011-04-26 2011-04-26 Una composicion de entacopone.

Country Status (11)

Country Link
US (1) US20140120166A1 (es)
EP (1) EP2702991A4 (es)
JP (1) JP5855230B2 (es)
KR (1) KR101807907B1 (es)
CN (1) CN103476406B (es)
AU (1) AU2011366717B2 (es)
BR (1) BR112013027219A2 (es)
CA (1) CA2833443C (es)
EA (1) EA025627B1 (es)
MX (1) MX2013012429A (es)
WO (1) WO2012145893A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101974752B1 (ko) * 2017-12-31 2019-09-05 황혜미 욕창 치료용 크림 및 이를 제조하는 방법
EP4117637A1 (en) * 2020-03-13 2023-01-18 Bial-Portela & CA, S.A. Micronised opicapone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
EP1364643A4 (en) * 2000-12-01 2009-07-15 Kyowa Hakko Kogyo Kk COMPOSITION WITH IMPROVED SOLUBILITY OR ORAL ABSORBIBILITY
EP1448169A1 (en) * 2001-11-07 2004-08-25 Fujisawa Pharmaceutical Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
CN1275593C (zh) * 2004-02-13 2006-09-20 马晶 一种枸橼酸他莫昔芬分散片及其制法
ES2311442T3 (es) * 2005-06-08 2010-01-07 Orion Corporation Un metood para la fabricacion de granulos que contienen entacapona para formas de dosificacion oral.
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP2114374A4 (en) * 2006-12-27 2011-03-23 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
BRPI0908052A2 (pt) 2008-02-06 2015-08-11 Wockhardt Research Center Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
ES2476765T3 (es) * 2008-08-22 2014-07-15 Wockhardt Limited Composición farmacéutica de liberación sostenida de entacapona o sales de la misma
EP2517704B1 (en) * 2009-12-25 2019-05-01 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof

Also Published As

Publication number Publication date
KR101807907B1 (ko) 2017-12-11
CA2833443C (en) 2017-11-07
CN103476406A (zh) 2013-12-25
EA025627B1 (ru) 2017-01-30
JP2014512395A (ja) 2014-05-22
KR20140024879A (ko) 2014-03-03
BR112013027219A2 (pt) 2016-12-27
AU2011366717B2 (en) 2017-06-15
EA201301197A1 (ru) 2014-02-28
WO2012145893A1 (zh) 2012-11-01
EP2702991A4 (en) 2015-02-18
AU2011366717A1 (en) 2013-11-07
CA2833443A1 (en) 2012-11-01
CN103476406B (zh) 2017-05-24
US20140120166A1 (en) 2014-05-01
JP5855230B2 (ja) 2016-02-09
EP2702991A1 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
SG10201804817TA (en) Delayed release compositions of linaclotide
MX348823B (es) Formulaciones estables de linaclotida.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
TW200942530A (en) Pyridine compounds
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
IN2012DN03807A (es)
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2011144733A3 (en) Dynamic double-circuit in-line heater
ZA201308177B (en) Process for the preparation of 1,3-butadiene and styrene copolymers and use thereof in vulcanizable elastomeric compositions
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
IL232712A (en) [1, 2, 4] Triazulophyridines and their use as phosphodiesterase inhibitors
PH12014502351A1 (en) Methods of producing anamorelin hydrochloride having controlled chloride content
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
MX2013012429A (es) Una composicion de entacopone.
WO2012065028A3 (en) Substituted tetracyclines
MX2012009537A (es) Formas solidas que comprenden un derivado de ciclopropilamida.
WO2012139074A3 (en) Migrastatins and uses thereof
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
WO2011107921A3 (en) Modified release composition of milnacipran